The Oncology Brothers and Sam Klempner, MD, offer comprehensive insights on treating residual disease in upper GI cancers following FLOT treatment.
SCRT/Chemo Produce Positive Responses in Locally Advanced Rectal Cancer
Results from the ShorTrip trial found that SCRT plus chemotherapy regimens showed promising efficacy for patients with locally advanced rectal cancer.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
EBC-129 Shows Early Activity in Advanced Pancreatic Ductal Adenocarcinoma
EBC-129 was well tolerated, with a safety profile consistent with other MMAE-based ADCs in patients with PDAC and other solid tumors.
Educating Patients and Clinicians on End-of-Life Care and Discussions
Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.
Adjuvant Nivolumab Provides Sustained Benefit in Resected Esophageal/GEJ Cancer
Five-year follow-up confirms adjuvant nivolumab's sustained disease-free and distant metastasis-free survival benefits in resected esophageal/GEJ cancer post-CRT.
NAPOLI-3 Post Hoc Review Highlights Long-Term Survival With NALIRIFOX in PDAC
A post hoc analysis of NAPOLI-3 reveals clinical characteristics and treatment strategies associated with long-term survival in patients with metastatic PDAC treated with NALIRIFOX.